Alpa Laboratories Limited (IN:ALPA)
:ALPA
Want to see IN:ALPA full AI Analyst Report?
ALPA Stock Chart & Stats
₹75.60
-₹1.63(-1.24%)
At close: 4:00 PM EST
₹75.60
-₹1.63(-1.24%)
Day’s Range― - ―
52-Week Range₹46.00 - ₹109.85
Previous CloseN/A
Volume65.27K
Average Volume (3M)2.75K
Market Cap
₹1.45B
Enterprise Value₹1.50B
Total Cash (Recent Filing)₹1.39B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)26.2
Beta1.65
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.86
Shares Outstanding21,040,600
10 Day Avg. Volume3,648
30 Day Avg. Volume2,746
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.52
Price to Sales (P/S)0.92
P/FCF Ratio11.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and steadily growing equity provide durable financial flexibility. A conservative capital structure limits refinancing risk, supports capex or product investment, and cushions earnings volatility, enabling steadier long-term operations and strategic optionality.
Consistent Retained Earnings / ROESteady equity accumulation and mid-single-digit ROE reflect an ability to generate returns while retaining capital for growth. This supports reinvestment, strengthens the capital base and underpins long-term competitiveness in domestic pharmaceutical distribution channels.
Improving Cash Generation In 2026Renewed operating cash flow and stronger 2026 free cash flow show the business can convert some earnings to cash. While variable historically, improved cash generation increases capacity to fund working capital and capex internally and reduces reliance on external financing over the medium term.
Bears Say
Operating Margin CollapseSharp compression in gross and operating margins signals structural pressure on core profitability, not just timing. Sustained margin deterioration threatens cash flow, reinvestment capacity and competitiveness unless product mix, pricing or cost structure is meaningfully improved.
Weak Cash ConversionPersistent low operating cash coverage versus reported earnings indicates working-capital strain or lower-quality earnings. This raises forecasting risk and limits the firm's ability to sustainably fund dividends, capex, or growth without external financing.
Revenue And EPS DeclineNegative revenue and steep EPS decline reflect weakening demand or pricing pressure in the latest year. Continued top-line and earnings erosion would impair margin recovery, reduce internally available funds, and increase execution risk for strategic initiatives over the medium term.
Alpa Laboratories Limited News
ALPA FAQ
What was Alpa Laboratories Limited’s price range in the past 12 months?
Alpa Laboratories Limited lowest stock price was ₹46.00 and its highest was ₹109.85 in the past 12 months.
What is Alpa Laboratories Limited’s market cap?
Alpa Laboratories Limited’s market cap is ₹1.45B.
When is Alpa Laboratories Limited’s upcoming earnings report date?
Alpa Laboratories Limited’s upcoming earnings report date is Aug 18, 2026 which is in 71 days.
How were Alpa Laboratories Limited’s earnings last quarter?
Alpa Laboratories Limited released its earnings results on May 29, 2026. The company reported ₹0.24 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.24.
Is Alpa Laboratories Limited overvalued?
According to Wall Street analysts Alpa Laboratories Limited’s price is currently Overvalued.
Does Alpa Laboratories Limited pay dividends?
Alpa Laboratories Limited does not currently pay dividends.
What is Alpa Laboratories Limited’s EPS estimate?
Alpa Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alpa Laboratories Limited have?
Alpa Laboratories Limited has 21,040,600 shares outstanding.
What happened to Alpa Laboratories Limited’s price movement after its last earnings report?
Alpa Laboratories Limited reported an EPS of ₹0.24 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.724%.
Which hedge fund is a major shareholder of Alpa Laboratories Limited?
Currently, no hedge funds are holding shares in IN:ALPA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alpa Laboratories Limited
Alpa Laboratories Limited engages in manufacturing, marketing, and selling pharmaceutical finished dosage forms in India. It offers ethical, generic, and over the counter products in various finished dosage forms, including injections, tablets, capsules, eye and ear drops, ointments, creams, and gels for human use; and boluses, injections, and intra-mammary infusions for veterinary use. The company also provides drugs in various categories, such as anti-infectives comprising antibacterial, antibiotics, antifungals, antiprotozoals, and antivirals; analgesics; anti-inflammatory drugs; cough and cold drugs; cardiovascular drugs; anti-diabetics; nutritional supplements; psychotropic drugs; and skin care preparations, as well as ear and eye care preparations. It sells its products through distributors, retail chemists, retail pharmacy stores, and hospitals. The company also exports its products to South and Central America, Africa, and Asia, and CIS countries. Alpa Laboratories Limited was founded in 1967 and is based in Indore, India.
Technical Analysis
Aarey Drugs & Pharmaceuticals Ltd.
―
Bafna Pharmaceuticals Limited
―
Bal Pharma Limited
―
Krebs Biochemicals & Industries Ltd.
―
Vaishali Pharma Ltd.
―